Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;8(18):1133.
doi: 10.21037/atm-20-4971.

Distinct clinicopathologic factors and prognosis based on the presence of ground-glass opacity components in patients with resected stage I non-small cell lung cancer

Chengdi Wang  1 , Yuxuan Wu  1 , Jingwei Li  1 , Pengwei Ren  1 , Ya Gou  1 , Jun Shao  1 , Yaojie Zhou  1 , Xue Xiao  1 , Paierhati Tuersun  1 , Dan Liu  1 , Li Zhang  2 , Weimin Li  1
Affiliations

Distinct clinicopathologic factors and prognosis based on the presence of ground-glass opacity components in patients with resected stage I non-small cell lung cancer

Chengdi Wang et al. Ann Transl Med. 2020 Sep.

Abstract

Background: This study was to investigate the prognostic value of ground-glass opacity(GGO) components and to evaluate distinct the clinicopathological variables of survival outcomes for the pure-GGO, part-solid and solid groups of patients with resected stage I non-small cell lung cancer (NSCLC).

Methods: We retrospectively reviewed the structured data for stage I NSCLC patients who had undergone the curative-intent surgical resection in the Lung Cancer Database of West China Hospital from 2009 to 2016. The eligible patients were divided into the pure-GGO, part-solid and solid groups according to the radiological manifestation. Univariate and multivariate Cox regression analyses were performed between the 3 groups. And we further evaluated the clinicopathological variables in each group separately.

Results: Among a total of 2,775 eligible patients enrolled into the cohort were 1,587 (57.19%) in the solid group, 508 (18.31%) in the part-solid group, and 680 (24.50%) in the pure-GGO group. The 5-year overall survival (OS) and recurrence-free survival (RFS) rates were 98.8% and 98.0% in the pure-GGO group, 96.0% and 86.5% in the part-solid group, and 88.0% and 75.5% in the solid group, respectively (P<0.001). Presence of GGO components was a significantly favorable prognosticator (HR =0.415, 95% CI: 0.286-0.601). Different groups had distinct prognostic factors. LVI was the shared risk factor for groups with presence of GGO components in both part-solid and pure-GGO groups. Pathological stage (IA or IB) was influential exclusively for the pure-GGO group. In the solid group, females, younger patients, and patients without VPI had better survival. But such independent significance did not exist in the other two groups.

Conclusions: GGO component was a strong prognosticator of better prognosis in resected patients with stage I NSCLC. Prognostic factors and survival outcomes were disparate among the pure-GGO, part-solid, and solid group. Our results support the proposal that the next edition tumor-node-metastasis (TNM) classification should consider the importance of GGO components as a new T descriptor.

Keywords: Non-small cell lung cancer (NSCLC); ground-glass opacity (GGO); part-solid nodule; solid nodule; survival analysis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-4971). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
OS (left) and RFS (right) curves in resected stage I NSCLC. OS, overall survival; RFS, recurrence-free survival; NSCLC, non-small cell lung cancer.
Figure 2
Figure 2
OS (left) and RFS (right) curves among the pure-GGO, part-solid, and solid groups in resected stage I NSCLC. OS, overall survival; RFS, recurrence-free survival; GGO, ground-glass opacity; NSCLC, non-small cell lung cancer.
Figure 3
Figure 3
OS (left) and RFS (right) curves among the stage IA1/IA2/IA3/IB in resected NSCLC. OS, overall survival; RFS, recurrence-free survival; NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75. 10.1016/S0140-6736(17)33326-3 - DOI - PMC - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503-13. 10.1056/NEJMoa1911793 - DOI - PubMed
    1. National Lung Screening Trial Research Team , Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed
    1. De Koning HJ, Van Der Aalst K, Ten Haaf M, et al. PL02.05 Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol 2018;13:S185. 10.1016/j.jtho.2018.08.012 - DOI